Abionyx: reduced net loss in 2023
Research and development costs rose to 1.52 million euros, as the company pursued the activities initiated in 2022, in particular clinical studies in renal and ophthalmology indications.
Abionyx is continuing to develop its strategic plan, and recalls that last October it carried out a capital increase, an operation which increased its financial visibility until the first quarter of 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction